McDermott + Bull has successfully placed Sean Rathbone as President of PNP Pharmaceuticals, a portfolio company of Gladius Partners. Based in Burnaby, British Columbia, PNP Pharmaceuticals is a unique contract manufacturer of nutraceutical and pharmaceutical products. Since its founding in 1999, PNP has rapidly grown to become one of Canada’s largest contract manufacturers of nutritional supplements with an emphasis on quality and service. Sean will work closely with Gladius’ managing partners and play a pivotal role in overseeing the day-to-day operations while positioning the company for its next phase of growth. Sean has 25 years of experience building and leading diverse teams in the areas of engineering, manufacturing, and operations within various highly regulated industries including healthcare, pharmaceuticals, and consumer beverages. Throughout his career, Sean has established a track record of success in creating collaborative teams to drive innovation and process improvements at Fortune 500 companies. Sean is a graduate of the University of Witwatersrand, in South Africa, and holds an MBA from Heriot-Watt University, in Scotland. Gladius Partners is a Vancouver-based boutique private equity firm that partners with well-established, profitable mid-market businesses in the Pacific Northwest. At Gladius, there is a commitment to a buy-and-hold “permanent private equity” strategy, focusing on long-term value creation and success instead of short-term gains. This executive search was completed by McDermott + Bull Managing Partner Paul Gibbons, Principal Nicholas Protti, Consultant Kate Klarich, and Research Associate Alina Ivanets.
McDermott + Bull Places President, PNP Pharmaceuticals
by McDermott + Bull | May 31, 2022 | Alina Ivanets, Canada, Canada Placement Announcement, Healthcare + Life Sciences, Healthcare + Life Sciences Placement Announcement, Paul Gibbons, Paul Gibbons Placement Announcement, Placement Announcement